Boston Partners Acquires 134,781 Shares of Lantheus Holdings, Inc. $LNTH

Boston Partners increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 30.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 576,362 shares of the medical equipment provider’s stock after acquiring an additional 134,781 shares during the period. Boston Partners’ holdings in Lantheus were worth $46,432,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Signaturefd LLC increased its stake in Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 116 shares during the period. Intrust Bank NA increased its stake in Lantheus by 2.9% in the 1st quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider’s stock worth $431,000 after buying an additional 125 shares during the period. Focus Financial Network Inc. lifted its holdings in Lantheus by 4.0% during the 2nd quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider’s stock valued at $293,000 after buying an additional 136 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Lantheus by 2.1% in the 1st quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider’s stock valued at $653,000 after buying an additional 139 shares during the period. Finally, Xponance Inc. boosted its position in Lantheus by 1.5% in the 1st quarter. Xponance Inc. now owns 9,931 shares of the medical equipment provider’s stock valued at $969,000 after buying an additional 145 shares during the period. Institutional investors own 99.06% of the company’s stock.

Insider Activity at Lantheus

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Rajiv A. Patel sold 3,365,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 2.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. JMP Securities decreased their price target on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. TD Cowen decreased their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Weiss Ratings cut Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. William Blair restated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Finally, B. Riley decreased their price objective on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $74.17.

Lantheus Price Performance

LNTH opened at $54.50 on Thursday. The firm has a market capitalization of $3.61 billion, a PE ratio of 14.49 and a beta of 0.04. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. The business’s 50-day moving average is $53.95 and its two-hundred day moving average is $67.46. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The business had revenue of $92.51 million for the quarter. Research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.